Page last updated: 2024-08-21

arsenic trioxide and Torsade de Pointes

arsenic trioxide has been researched along with Torsade de Pointes in 8 studies

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's7 (87.50)29.6817
2010's1 (12.50)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Gill, H; Hai, JJ; Kumana, CR; Kwong, YL; Siu, CW; Tse, HF1
Barbey, JT; Pezzullo, JC; Soignet, SL1
Bertol, E; Fineschi, V; Karch, SB; Mari, F1
Ebert, SN; Katchman, AN; Koerner, J; Tosaka, T; Woosley, RL1
Kobayashi, M; Naito, K; Nakamura, S; Ohnishi, K; Ohno, R; Sahara, N; Shigeno, K; Shinjo, K; Takeshita, A; Tobita, T1
Api, M; Chiaramida, S; Dutcher, JP; Garl, S; Lucariello, R; Unnikrishnan, D; Varshneya, N; Wiernik, PH1
Barbey, JT1
Singer, JW1

Reviews

1 review(s) available for arsenic trioxide and Torsade de Pointes

ArticleYear
Cardiac toxicity of arsenic trioxide.
    Blood, 2001, Sep-01, Volume: 98, Issue:5

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Artifacts; Electrocardiography; Electrolytes; Humans; Leukemia; Long QT Syndrome; Oxides; Torsades de Pointes

2001

Other Studies

7 other study(ies) available for arsenic trioxide and Torsade de Pointes

ArticleYear
Torsade de Pointes during oral arsenic trioxide therapy for acute promyelocytic leukemia in a patient with heart failure.
    Annals of hematology, 2015, Volume: 94, Issue:3

    Topics: Administration, Oral; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Heart Failure; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Torsades de Pointes

2015
Effect of arsenic trioxide on QT interval in patients with advanced malignancies.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Oct-01, Volume: 21, Issue:19

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Clinical Trials as Topic; Electrocardiography; Female; Humans; Leukemia, Promyelocytic, Acute; Long QT Syndrome; Male; Middle Aged; Neoplasms; Oxides; Retrospective Studies; Torsades de Pointes

2003
Channelling the Emperor: what really killed Napoleon?
    Journal of the Royal Society of Medicine, 2004, Volume: 97, Issue:8

    Topics: Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Cause of Death; France; History, 19th Century; Humans; Oxides; Stomach Neoplasms; Torsades de Pointes

2004
Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs.
    The Journal of pharmacology and experimental therapeutics, 2006, Volume: 316, Issue:3

    Topics: Animals; Arsenic Trioxide; Arsenicals; Cells, Cultured; Electrocardiography; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Haloperidol; Humans; Loratadine; Lovastatin; Methadone; Oxides; Pentamidine; Potassium Channel Blockers; Rabbits; Terfenadine; Torsades de Pointes

2006
Two cases of acute promyelocytic leukemia complicated by torsade de pointes during arsenic trioxide therapy.
    International journal of hematology, 2006, Volume: 83, Issue:4

    Topics: Adult; Anthracyclines; Antifungal Agents; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cardiomyopathies; Female; Fluconazole; Humans; Hypokalemia; Leukemia, Promyelocytic, Acute; Middle Aged; Oxides; Time Factors; Torsades de Pointes

2006
Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide.
    Blood, 2001, Mar-01, Volume: 97, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Monitoring; Electrocardiography; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Oxides; Torsades de Pointes

2001
Cardiac toxicity of arsenic trioxide.
    Blood, 2001, Sep-01, Volume: 98, Issue:5

    Topics: Adverse Drug Reaction Reporting Systems; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Drug Approval; Drug Industry; Drug Labeling; Electrocardiography; Electrolytes; Humans; Leukemia; Long QT Syndrome; Oxides; Practice Guidelines as Topic; Safety; Torsades de Pointes; United States; United States Food and Drug Administration

2001